Black Diamond Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a price target of $20.
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a price target of $20.
July 31, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James initiated coverage on Black Diamond Therapeutics with an Outperform rating and a $20 price target, causing the stock to trade higher.
The initiation of coverage with an Outperform rating and a specific price target by a reputable firm like Raymond James is likely to positively influence investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100